Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adams Diversified Equity Fund, Inc. is a publicly owned investment manager. The firm provides its services to investment companies. The firm invests in the public equity markets of the United States. It invests in stocks of large-cap companies across diversified sectors to make its investments. The firm employs a fundamental, technical and quantitative analysis with a bottom-up stock picking approach, while focusing on earnings growth prospects, financial strength, cash flow generation, macro-economics, capital allocation, market competition, profitability. It obtains external research to complement its in-house research to make its investments. The firm benchmarks the performance of its portfolios against the S&P 500 Index. It was formerly known as The Adams Express Company. Adams Diversified Equity Fund, Inc. was founded in 1840 and is based in Baltimore, Maryland.

Adams Diversified Equity Fund, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BALTIMORE, NOV. 13, 2025 (GLOBE NEWSWIRE) -- ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) DECLARED TODAY A DISTRIBUTION OF $0.46 PER SHARE PAYABLE DECEMBER 23, 2025 TO SHAREHOLDERS OF RECORD ON NOVEMBER 21, 2025. THE DISTRIBUTION IS OPTIONALLY PAYABLE IN ADDITIONAL SHARES OF COMMON STOCK (DEFAULT) OR IN CASH BY SPECIFIC STOCKHOLDER ELECTION RECEIVED BEFORE 4 P.M.

ADAMS DIVERSIFIED EQUITY FUND DECLARES DISTRIBUTION

BALTIMORE, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) TODAY ANNOUNCED THE FUND'S INVESTMENT RETURNS FOR THE FIRST NINE MONTHS OF 2025. THE TOTAL RETURN ON THE FUND'S NET ASSET VALUE FOR THE FIRST NINE MONTHS OF 2025 WAS 16.0%, WITH DIVIDENDS AND CAPITAL GAINS REINVESTED. THIS COMPARED TO 14.8% TOTAL RETURN FOR THE S&P 500 INDEX AND 13.4% TOTAL RETURN FOR THE MORNINGSTAR U.S. LARGE BLEND CATEGORY. THE TOTAL RETURN ON THE FUND'S MARKET PRICE FOR THE PERIOD WAS 17.8%.

ADAMS DIVERSIFIED EQUITY FUND REPORTS NINE MONTH RESULTS

LONDON, AUG. 22, 2025 (GLOBE NEWSWIRE) -- DIGINEX LIMITED (DIGINEX) (NASDAQ: DGNX), A LEADING PROVIDER OF SUSTAINABILITY REGTECH SOLUTIONS, TODAY PROVIDED AN UPDATE ON ITS MEMORANDUM OF UNDERSTANDING (MOU) BETWEEN THE COMPANY AND NOMAS GLOBAL INVESTMENTS LLC S.P.C, A SOLELY OWNED SPV OF HIS HIGHNESS SHAIKH MOHAMMED BIN SULTAN BIN HAMDAN AL NAHYAN OF ABU DHABI'S ROYAL FAMILY (NOMAS), DATED 17 MARCH 2025. THE INTENTION OF THE MOU WAS TO SECURE A DUAL-LISTING OF DIGINEX'S SECURITIES ON THE ABU DHABI SECURITIES EXCHANGE (ADX), TO EXPAND DIGINEX'S BUSINESS IN THE GULF COOPERATION COUNCIL (GCC) AND A POTENTIAL CAPITAL RAISE FOR DIGINEX OF UP TO USD$250 MILLION FOCUSED ON LARGE INSTITUTIONAL INVESTORS BASED IN THE GCC. NUMEROUS MEETINGS HAVE BEEN HELD WITHIN THE UNITED ARAB EMIRATES (UAE) TO PURSUE A DUAL-LISTING ON THE ADX, AND WHILE THE PROCESS IS STILL ON-GOING, IT NOW APPEARS THAT IT WILL TAKE A FEW MORE MONTHS IF NOT LONGER TO SUCCESSFULLY LIST THE COMPANY'S ORDINARY SHARES ON THE ADX. ADDITIONALLY, THE POTENTIAL USD$250 MILLION CAPITAL RAISE, IF IT OCCURS, WILL MOST LIKELY OCCUR FOLLOWING THE LISTING OF DIGINEX'S ORDINARY SHARES ON THE ADX. HIS HIGHNESS AND NOMAS REMAIN ACTIVE SUPPORTERS OF DIGINEX AND ARE CURRENTLY WORKING TO ASSIST DIGINEX TO GET LISTED ON THE ADX AND TO EXPAND ITS BUSINESS IN THE UAE AND GCC.

DIGINEX PROVIDES UPDATE ON MOU FOR ADX DUAL LISTING, POTENTIAL CAPITAL RAISE, AND REGIONAL UAE AND GCC EXPANSION

LEXINGTON, MASS.--(BUSINESS WIRE)--ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) (ALDEYRA) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DESIGNATION FOR ADX-2191 (METHOTREXATE INTRAVITREAL INJECTION) FOR THE TREATMENT OF INHERITED RETINAL DYSTROPHIES OF THE ROD-DOMINANT PHENOTYPE, INCLUDING RETINITIS PIGMENTOSA. THERE ARE CURRENTLY NO APPROVED DRUG TREATMENTS FOR PATIENTS WITH MOST FORMS OF RETINITIS PIGMENTOSA, A CLINICAL GROUP OF RARE GENETIC EYE DISEASES CHARACTERIZ.

ALDEYRA THERAPEUTICS RECEIVES ORPHAN DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR ADX-2191 FOR THE TREATMENT OF INHERITED RETINAL DYSTROPHIES INCLUDING RETINITIS PIGMENTOSA

BALTIMORE, JULY 18, 2025 (GLOBE NEWSWIRE) -- ON JULY 17, 2025, ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) DECLARED A DISTRIBUTION OF $0.46 PER SHARE PAYABLE AUGUST 28, 2025 TO SHAREHOLDERS OF RECORD ON JULY 28, 2025. THE DISTRIBUTION IS OPTIONALLY PAYABLE IN ADDITIONAL SHARES OF COMMON STOCK (DEFAULT) OR IN CASH BY SPECIFIC STOCKHOLDER ELECTION RECEIVED BEFORE 4 P.M. (ET) ON AUGUST 15, 2025, THE VALUATION DATE. THE ISSUE PRICE FOR SHARES WILL BE THE FUND'S CLOSING NYSE MARKET PRICE ON THE VALUATION DATE.

BALTIMORE, JULY 17, 2025 (GLOBE NEWSWIRE) -- ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) ANNOUNCES THE FUND'S INVESTMENT RETURNS FOR THE FIRST HALF OF 2025. THE TOTAL RETURN ON THE FUND'S NET ASSET VALUE FOR THE FIRST HALF OF 2025 WAS 7.8%, WITH DIVIDENDS AND CAPITAL GAINS REINVESTED. THIS COMPARED TO 6.2% TOTAL RETURN FOR THE S&P 500 INDEX AND 5.7% TOTAL RETURN FOR THE MORNINGSTAR U.S. LARGE BLEND CATEGORY. THE TOTAL RETURN ON THE FUND'S MARKET PRICE FOR THE PERIOD WAS 12.4%.

ADAMS DIVERSIFIED EQUITY FUND ANNOUNCES FIRST HALF 2025 PERFORMANCE

LEXINGTON, MASS.--(BUSINESS WIRE)--ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) (ALDEYRA) TODAY ANNOUNCED RECEIPT OF A SPECIAL PROTOCOL ASSESSMENT AGREEMENT LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR ADX-2191 (METHOTREXATE INJECTION, USP), AN INVESTIGATIONAL DRUG CANDIDATE, FOR THE TREATMENT OF PRIMARY VITREORETINAL LYMPHOMA (PVRL), A RARE AND POTENTIALLY FATAL CANCER CURRENTLY LACKING FDA-APPROVED THERAPY. PRIMARY VITREORETINAL LYMPHOMA IS TREATED TODAY OFF LABEL WITH INTRAVITRE.

ALDEYRA THERAPEUTICS RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ADX-2191 FOR THE TREATMENT OF PRIMARY VITREORETINAL LYMPHOMA

BALTIMORE, APRIL 21, 2025 (GLOBE NEWSWIRE) -- ON APRIL 17, 2025, ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) DECLARED A DISTRIBUTION OF $0.46 PER SHARE PAYABLE MAY 30, 2025 TO SHAREHOLDERS OF RECORD ON APRIL 28, 2025. THE DISTRIBUTION IS OPTIONALLY PAYABLE IN ADDITIONAL SHARES OF COMMON STOCK (DEFAULT) OR IN CASH BY SPECIFIC STOCKHOLDER ELECTION RECEIVED BEFORE 4 P.M.

BALTIMORE, APRIL 17, 2025 (GLOBE NEWSWIRE) -- ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) ANNOUNCES THE FUND'S INVESTMENT RETURNS FOR THE FIRST QUARTER OF 2025. THE TOTAL RETURN ON THE FUND'S NET ASSET VALUE FOR THE FIRST QUARTER OF 2025 WAS -3.9%, WITH DIVIDENDS AND CAPITAL GAINS REINVESTED. THIS COMPARED TO -4.3% TOTAL RETURN FOR BOTH THE S&P 500 INDEX AND THE MORNINGSTAR U.S. LARGE BLEND CATEGORY. THE TOTAL RETURN ON THE FUND'S MARKET PRICE FOR THE PERIOD WAS -3.9%.

ADAMS DIVERSIFIED EQUITY FUND ANNOUNCES FIRST QUARTER 2025 PERFORMANCE

BALTIMORE, JAN. 17, 2025 (GLOBE NEWSWIRE) -- ADAMS DIVERSIFIED EQUITY FUND, INC. (NYSE: ADX) HAS DECLARED A DISTRIBUTION OF $0.47 PER SHARE PAYABLE FEBRUARY 28, 2025 TO SHAREHOLDERS OF RECORD ON JANUARY 27, 2025, INCLUDING $0.03 NET INVESTMENT INCOME, $0.12 SHORT-TERM CAPITAL GAIN, AND $0.19 LONG-TERM CAPITAL GAIN REALIZED IN 2024 AND $0.13 FROM 2025 SOURCES. THE FULL DISTRIBUTION IS OPTIONALLY PAYABLE IN ADDITIONAL SHARES OF COMMON STOCK (DEFAULT) OR IN CASH BY SPECIFIC STOCKHOLDER ELECTION RECEIVED BEFORE 4 P.M. (ET) ON FEBRUARY 14, 2025, THE VALUATION DATE. THE ISSUE PRICE FOR SHARES WILL BE THE FUND'S CLOSING NYSE MARKET PRICE ON THE VALUATION DATE.

Adams Diversified Equity Fund, Inc.

ADX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Adams Diversified Equity Fund, Inc.

ADX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ADX